Futures
Access hundreds of perpetual contracts
TradFi
Gold
One platform for global traditional assets
Options
Hot
Trade European-style vanilla options
Unified Account
Maximize your capital efficiency
Demo Trading
Introduction to Futures Trading
Learn the basics of futures trading
Futures Events
Join events to earn rewards
Demo Trading
Use virtual funds to practice risk-free trading
Launch
CandyDrop
Collect candies to earn airdrops
Launchpool
Quick staking, earn potential new tokens
HODLer Airdrop
Hold GT and get massive airdrops for free
Pre-IPOs
Unlock full access to global stock IPOs
Alpha Points
Trade on-chain assets and earn airdrops
Futures Points
Earn futures points and claim airdrop rewards
More
Buy Rating on Boston Scientific’s Watchman FLX Backed by Champion Trial Success and Accelerating LAAC Market Growth
Analyst Josh Jennings from TD Cowen maintained a Buy rating on Boston Scientific (BSX) with a $100 price target, citing the strong Champion trial results for the Watchman FLX device. The trial demonstrated lower non-procedural bleeding rates compared to NOACs while maintaining comparable stroke protection, validating the device’s clinical appeal and safety. This success is expected to drive a roughly 20% annual expansion in the left atrial appendage closure market, leading to enhanced physician confidence and sustained long-term growth for BSX.